Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)

NCT01757665 · View on ClinicalTrials.gov ↗

Study Summary

The objective of this trial is to confirm that the modifications to tissue processing, valve sterilization and packaging do not raise any new questions of safety and effectiveness in subjects who require replacement of their native or prosthetic aortic or mitral valve.

Interventions

  • DEVICE Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000M

Study Locations (20)

New York

  • New York Weill Cornell Medical Center — New York
  • Mount Sinai Morningside — New York
  • Icahn School of Medicine at Mount Sinai — New York
  • New York Presbyterian Hospital - Columbia University Medical Center — New York

California

  • University of Southern California — Los Angeles
  • Sutter Institute for Medical Research — Sacramento
  • Board of Trustees of the Leland Stanford Junior University — Stanford

Florida

  • Shands at the University of Florida — Gainesville
  • Florida Hospital — Orlando

Missouri

  • Missouri Baptist Medical Center — St Louis
  • Washington University/ Barnes Jewish Hospital — St Louis

Alabama

  • Cardiology, P.C. — Birmingham

Connecticut

  • Yale-New Haven — New Haven

Georgia

  • Emory University Hospital Midtown — Atlanta

Indiana

  • St. Vincent Heart Center of Indiana — Indianapolis

Trial Details

FieldValue
Enrollment Target 777 participants
Start Date 2012-12-11
Est. Completion 2026-08
Phase NA

Sponsor

Edwards Lifesciences

34 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01757665

The ClinicalTrials.gov registry entry for NCT01757665 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 777 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edwards Lifesciences, which has 34 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 5 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention — of which Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000M is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01757665 reports 20 study locations spanning 13 distinct geographic areas — top geographies include New York, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01757665 about?

NCT01757665 is a clinical study titled "ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)". The objective of this trial is to confirm that the modifications to tissue processing, valve sterilization and packaging do not raise any new questions of safety and effectiveness in subjects who require replacement of their native or prosthetic aortic or mitral valve.

What is the current status of trial NCT01757665?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 777 participants. The study started on 2012-12-11. Estimated completion is 2026-08.

What conditions does trial NCT01757665 study?

This clinical trial studies the following conditions: Heart Failure, Aortic Stenosis, Aortic Valve Insufficiency, Mitral Valve Insufficiency, Mitral Stenosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01757665?

The interventions under investigation include: Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000M (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01757665?

This trial is sponsored by Edwards Lifesciences, which has 34 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01757665 being conducted?

This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial